Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 2/20 | 0.54 |
| ▸ | CES1 | P23141 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132367 | 0.87 | LMNA (0.73) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL3842531 | 0.87 | LMNA (0.73) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL9126141 | 0.87 | LMNA (0.73) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL52200 | 0.87 | ALDH1A1 (1.00) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL822185 | 0.87 | ALDH1A1 (1.00) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL5388314 | 0.86 | CES2 (0.76) | LMNAALDH1A1RAB9AHTTMAPT | |
| SCHEMBL11528213 | 0.85 | ALDH1A1 (0.94) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL29984922 | 0.85 | LMNA (0.70) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| SCHEMBL12812885 | 0.85 | RAB9A (0.55) | LMNAALDH1A1SRD5A2RAB9AHTT | |
| Ethylene SCHEMBL10490014 | 0.82 | LMNA (0.67) | LMNAALDH1A1SRD5A2RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692072-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025041624-A1 | PHOTOCHROMIC COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-02-27 | — | — | WO | disclosed |
| WO-2025041625-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASSES | 株式会社トクヤマ | 2025-02-27 | — | — | WO | disclosed |
| WO-2025028365-A1 | PHOTOCHROMIC COMPOUND, PHENOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2025-02-06 | — | — | WO | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| WO-2024202087-A1 | PHOTOCHROMIC COMPOUND, PROPARGYL ALCOHOL COMPOUND, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND SPECTACLES | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| EP-3555096-B1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-23 | — | — | EP | disclosed |
| CN-114685505-A | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-110312719-B | Imidazopyrrolopyridines as JAK family kinase inhibitors | 詹森药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-1373266-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-0958280-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999023072-A1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1999-05-14 | — | — | WO | disclosed |
| EP-0085959-B1 | AROMATIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-04-19 | — | — | EP | disclosed |
| EP-0085959-A2 | Aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827638-B2 | Imidazopyrrolopyridine as inhibitors of the JAK family of kinases | JAK1, JAK2, JAK3 | LMNA 4330/4885ALDH1A1 2835/4885SRD5A2 4313/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | LMNA 4729/4885ALDH1A1 177/4885SRD5A2 1245/4885 |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | LMNA 1454/4885ALDH1A1 837/4885SRD5A2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.